D.E. Shaw & Co’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

D.E. Shaw & Co’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-40,000	Closed	-$1.88M	–	4438
2019 Q4	$1.88M	Buy	+40,000	New	+$1.77M	﹤0.01%	2527

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

D.E. Shaw & Co's RARX Position: Q2 2020 in Review

D.E. Shaw & Co sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 25,580 shares — an estimated $1.23M sold.

D.E. Shaw & Co first reported a position in RARX in Q4 2016 and held it in 11 quarters. The position peaked at $12.5M in Q2 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

D.E. Shaw & Co reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
D.E. Shaw & Co sold 25,580 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1.23M.
D.E. Shaw & Co first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 11 quarters.
D.E. Shaw & Co's Ra Pharmaceuticals, Inc. Common Stock position peaked at $12.5M in Q2 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on D.E. Shaw & Co's 13F filing for Q2 2020, filed 14 Aug 2020.